Compare NCMI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | LEXX |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 22.7M |
| IPO Year | 2007 | N/A |
| Metric | NCMI | LEXX |
|---|---|---|
| Price | $4.09 | $1.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $6.88 | $4.00 |
| AVG Volume (30 Days) | ★ 417.5K | 152.2K |
| Earning Date | 10-30-2025 | 01-09-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,300,000.00 | $705,923.00 |
| Revenue This Year | $3.66 | $13.35 |
| Revenue Next Year | $12.17 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $3.81 | $0.77 |
| 52 Week High | $7.60 | $2.43 |
| Indicator | NCMI | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 71.54 |
| Support Level | $4.06 | $1.05 |
| Resistance Level | $4.25 | $1.17 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 22.22 | 77.27 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.